Phase II Trial Evaluating the Efficacy of 177Lutetium-PSMA-617 Treatment in Patients With Metastatic Clear Cell Renal Carcinoma Cell With Progressive Disease on First-line or Second-line Systemic Treatment
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Jan 2025 New trial record